Company Analysis

Bolt Biotherapeutics, Inc. (BOLT)

Nasdaq: BOLT · Pharmaceutical Preparations · Redwood City, CA · filing with the SEC since 2015
Grade4.8
◀ Past 6.8● Present 4.5▶ Future 3.7
1 est.

Filings

156 filings since 2017 beside 142 insider forms · and emerging growth company · read from EDGAR on Nov 13, 2026
Due next and emerging growth company
10-K Annual report for the fiscal year ending Dec 31, 2026Non-accelerated filers and smaller reporting companies have 90 days after the fiscal year ends. by Mar 31, 2027
10-Q Quarterly report for the quarter ending Mar 31, 2027Non-accelerated filers and smaller reporting companies have 45 days after the quarter ends; quarter ends are taken to the month end. by May 15, 2027

A deadline is the latest date the SEC's rules allow for its filer category. It is not a forecast of the day the company files. Last time, the results release (8-K item 2.02) came 43 days after the quarter ended. The proxy statement was last filed Apr 28, 2026.

Filings a yearinsider forms included
16765240424336
20192020202120222023202420252026

2026 counts to Nov 13, 2026.

Officer or director change (8-K item 5.02): 4 times in the last 36 months, the newest Oct 23, 2026.Listing warning from its exchange (8-K item 3.01): 3 times in the last 36 months, the newest Jun 6, 2025.
Insider forms 142

Insider forms (3, 4, 5 and 144) are counted each year but not listed here; the people and their trades are on the Ownership tab.

FiledFormWhat it is, in plain wordsPeriodAsk
Nov 13, 2026 10-Q Quarterly report Sep 30, 2026
Nov 12, 2026 8-K items 2.02, 9.01 Results released · Current report
Nov 12, 2026 SCHEDULE 13G/A Large holder update, amended
Nov 6, 2026 SCHEDULE 13G Large holder notice
Oct 6, 2026 8-K item 1.01 Major agreement signed · Current report Oct 1, 2026
Aug 13, 2026 SCHEDULE 13G Large holder notice
Aug 11, 2026 10-Q Quarterly report Jun 30, 2026
Aug 11, 2026 8-K items 2.02, 9.01 Results released · Current report
Jun 11, 2026 8-K item 5.07 Shareholder vote · Current report
May 12, 2026 10-Q Quarterly report Mar 31, 2026
May 12, 2026 8-K items 2.02, 9.01 Results released · Current report
Apr 28, 2026 ARS Annual report to shareholders Dec 31, 2025
Apr 28, 2026 DEFA14A Extra proxy material
Apr 28, 2026 DEF 14A Proxy statement Apr 27, 2026
Mar 12, 2026 S-8 Employee stock plan registration
Mar 12, 2026 10-K Annual report Dec 31, 2025
Mar 12, 2026 8-K items 2.02, 9.01 Results released · Current report
Feb 26, 2026 SCHEDULE 13D/A Activist holder update, amended
Feb 17, 2026 SCHEDULE 13D/A Activist holder update, amended
Feb 13, 2026 SCHEDULE 13G/A Large holder update, amended
Nov 14, 2025 SCHEDULE 13G/A Large holder update, amended
Nov 14, 2025 SCHEDULE 13G/A Large holder update, amended
Nov 12, 2025 10-Q Quarterly report Sep 30, 2025
Nov 12, 2025 8-K items 2.02, 9.01 Results released · Current report
Oct 2, 2025 8-K items 2.05, 8.01 Exit or restructuring costs; Other event · Current report Oct 1, 2025
Aug 14, 2025 10-Q Quarterly report Jun 30, 2025
Aug 14, 2025 8-K items 2.02, 9.01 Results released · Current report
Aug 14, 2025 SCHEDULE 13G/A Large holder update, amended
Jun 6, 2025 8-K items 3.01, 5.03 Listing warning from its exchange; Charter, bylaw or fiscal-year change · Current report
Jun 4, 2025 8-K item 8.01 Other event · Current report
May 28, 2025 8-K item 5.07 Shareholder vote · Current report May 27, 2025
May 15, 2025 SCHEDULE 13G/A Large holder update, amended
May 12, 2025 10-Q Quarterly report Mar 31, 2025
May 12, 2025 8-K items 2.02, 9.01 Results released · Current report
Apr 25, 2025 ARS Annual report to shareholders Dec 31, 2024
Apr 25, 2025 DEF 14A Proxy statement May 27, 2025
Apr 16, 2025 8-K items 5.03, 9.01 Charter, bylaw or fiscal-year change · Current report Apr 15, 2025
Apr 16, 2025 PRE 14A Preliminary proxy statement May 27, 2025
Apr 15, 2025 DEF 14A Proxy statement May 27, 2025
40 of 156 shown

Every row opens the filing on EDGAR. The plain words are the site's own for each form and each 8-K item; the complete history, insider forms included, is on EDGAR.

SI Assistanton BOLT · research, not advice